Infectious Diseases

The study, published Wednesday in the Canadian Medical Association Journal, is the largest single-country trial of remdesivir reported to date.

Pfizer’s Paxlovid expected to overshadow Merck’s molnupiravir, with higher efficacy in preventing hospitalization/death in high-risk outpatients with mild/moderate COVID-19.

In Canada, a conservative estimate is that long COVID has affected 100,000 to 150,000 people so far, although the studies assessing prevalence have serious methodologic flaws.

It's still unclear when shipments will start or how much Canada will get at first as supply issues for the American-made drug have made it incredibly hard to get even in the United States, where it was authorized before Christmas.

Study investigates the incidence of false-positives in a large sample of SARS-CoV-2 rapid antigen tests used to screen asymptomatic workers throughout Canada.

But vaccination still offers protection, study finds

Treatment was thought to potentially have beneficial effects against COVID-19–mediated hyperactivated inflammatory response.

Laboratory testing shows the drug retains its potency against the omicron variant, the company announced, as many experts had predicted.